Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.

Bioorganic chemistry - 1 Apr 2022

Yen Shih-Chung, Chen Liang-Chieh, Huang Han-Li, HuangFu Wei-Chun, Chen Yi-Ying, Eight Lin Tony, Lien Ssu-Ting, Tseng Hui-Ju, Sung Tzu-Ying, Hsieh Jui-Hua, Huang Wei-Jan, Pan Shiow-Lin, Hsu Kai-Cheng

Abstract excerpt

Fms-like tyrosine kinase 3 (FLT3) is considered a promising therapeutic target for acute myeloid leukemia (AML) in the clinical. However, monotherapy with FLT3 inhibitor is usually accompanied by drug resistance. Dual inhibitors might be therapeutically beneficial to patients with AML due to their ability to overcome drug resistance. Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) phosphorylate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Intracellular Signaling Peptides and Proteins

Share to Leukemia, Myeloid, Acute

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 35182882
DOI: 10.1016/j.bioorg.2022.105675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.PMID 35182882Read ↗

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid LeukemiaSemantic proximity Read ↗

O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.Semantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read ↗

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.Semantic proximity Read ↗

Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.Semantic proximity Read ↗

Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.Semantic proximity Read ↗

Recent Advances in FLT3 Inhibitors for Acute Myeloid LeukemiaSemantic proximity Read ↗

Novel FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.